Dose matters: a dose-stratified real-world analysis of magnesium sulfate in preventing cisplatin-induced nephrotoxicity
Supportive Care in Cancer · 2026-04 · 34 (4)
DOI: 10.1007/s00520-026-10485-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 07.03.2026. Verfasst von Arif Hakan Önder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Antalya Educational and Research Hospital, Antalya, Turkey. dr_hakanonder@hotmail.com. Hauptthemen laut MEDLINE: Cisplatin, Magnesium Sulfate, Acute Kidney Injury, Antineoplastic Agents. Die Arbeit nennt 15 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Intravenous magnesium supplementation is increasingly adopted as a nephroprotective measure in patients receiving cisplatin-based chemotherapy, particularly in several Asian and European oncology centers. However, the dose-dependent nature of this effect remains poorly defined, and most studies have not addressed long-term renal outcomes. METHODS: In this multicenter retrospective study, 287 patients undergoing weekly cisplatin-based chemoradiotherapy for head and neck or cervical cancer were stratified based on prophylactic magnesium dose: 12 mEq or 24 mEq IV magnesium sulfate. Serum creatinine (sCr) and estimated glomerular filtration rate (eGFR) were measured at baseline, during treatment, and up to 12 months post-treatment. The incidence of acute kidney injury (AKI) was defined using CTCAE v5.0 criteria. Comparative analysis was performed using standard statistical tests, and results were contextualized with recent large-scale cohort findings. RESULTS: AKI incidence was 17.7% in the 12 mEq group and 13.2% in the 24 mEq group (p = 0.32). However, longitudinal renal follow-up revealed a significant divergence in sCr and eGFR trajectories: the 24 mEq cohort maintained near-baseline renal function, whereas the 12 mEq group exhibited progressive deterioration at 6 and 12 months. These findings contrast with prior binary exposure studies and indicate a sustained, dose-dependent protective effect. CONCLUSIONS: Magnesium's renoprotective benefit in cisplatin-based therapy is not only determined by its presence, but also by its dose. Our results support the incorporation of standardized magnesium dosing, specifically a minimum of 24 mEq, into clinical protocols. Dose precision, not merely inclusion, should guide prophylactic strategies to ensure effective renal protection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Antalya Educational and Research Hospital, Antalya, Turkey. dr_hakanonder@hotmail.com.
- Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey.
- Department of Medical Oncology, Antalya Educational and Research Hospital, Antalya, Turkey.
Zitieren
APA
Önder, A. H., İlhan, Y., & Çatlı, M. M. (2026). Dose matters: a dose-stratified real-world analysis of magnesium sulfate in preventing cisplatin-induced nephrotoxicity. Supportive Care in Cancer, 34(4). https://doi.org/10.1007/s00520-026-10485-5
Vancouver
Önder AH, İlhan Y, Çatlı MM. Dose matters: a dose-stratified real-world analysis of magnesium sulfate in preventing cisplatin-induced nephrotoxicity. Supportive Care in Cancer. 2026;34(4). doi:10.1007/s00520-026-10485-5
BibTeX
@article{nder2026,
author = {Önder, Arif Hakan and İlhan, Yusuf and Çatlı, Mehmet Mutlu},
title = {Dose matters: a dose-stratified real-world analysis of magnesium sulfate in preventing cisplatin-induced nephrotoxicity},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {4},
doi = {10.1007/s00520-026-10485-5}
}
EUVIMED